[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fTcC2aMt2tR56Xe5FsQ02cb6pRCqHZCcrv8OKwVk-VbY":8,"$fmmZA48ArHruEevTQX2RWuuYuyg0395zBV8xOH71DM_0":55,"$fTxn2ISPWzmAt0P_OO2AAldui3dKC02G0-0NMf2Ox-Z0":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},61756,870487,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//PHYb6CWVMq3UjJiVWGBALbe3OtlRn9En.png","朱旭东","浙江大学医学院附属第一医院","肿瘤科","主治医师",9,0,"了解滤泡性淋巴瘤WHO 3A级药品的使用要点","","https://ystcdn.venuertc.com/venue/AI/9cbdc4e9-e4c8-4682-ad97-927c72d0a0f9.jpg","\u003Cdiv id=\"material_title\" class=\"med-fl_lymphoma-title\">\n  了解滤泡性淋巴瘤WHO 3A级药品的使用要点\n\u003C/div>\n\n\u003Cdiv class=\"med-fl_lymphoma-intro med-fl_lymphoma-bg\">\n  \u003Cp>说起来，在针对滤泡性淋巴瘤WHO 3A级的治疗中，药品选择尤为重要。化疗药、单克隆抗体和靶向药是临床常用的核心药物。正确使用这些药品，能最大程度提高治疗效果，同时减少副作用风险。下面，我们梳理了六个关键用药细节，帮助大家用药更安心、更规范。💊\u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"med-fl_lymphoma-section med-fl_lymphoma-bg1\">\n  \u003Ch2 class=\"med-fl_lymphoma-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01. 药品主成分与剂型解析\u003C/h2>\n  \u003Cul>\n    \u003Cli>\u003Cstrong>单克隆抗体药物\u003C/strong>：最常用的是利妥昔单抗（Rituximab），属于抗CD20抗体。其主要剂型为注射液，每瓶规格一般为100mg/10ml或500mg/50ml。\u003C/li>\n    \u003Cli>\u003Cstrong>化疗药品\u003C/strong>：包括环磷酰胺（Cyclophosphamide）、多柔比星（Doxorubicin）、长春新碱（Vincristine）等。主要为注射剂型，按照体表面积计算剂量。\u003C/li>\n    \u003Cli>\u003Cstrong>靶向药物\u003C/strong>：如伊布替尼（Ibrutinib）、奥比利尤单抗（Obinutuzumab）等，部分为口服片剂，需严格遵循剂量。\u003C/li>\n  \u003C/ul>\n  \u003Cdiv class=\"med-fl_lymphoma-tips-bg\">\n    \u003Cspan class=\"med-fl_lymphoma-emoji\">🧬\u003C/span>\n    \u003Cspan>使用时需区分注射和口服剂型，绝不混用。\u003C/span>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"med-fl_lymphoma-section med-fl_lymphoma-bg2\">\n  \u003Ch2 class=\"med-fl_lymphoma-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02. 药理机制概述（不涉具体用法）\u003C/h2>\n  \u003Cul>\n    \u003Cli>\u003Cstrong>利妥昔单抗\u003C/strong>：通过与B细胞表面CD20抗原结合，促使B细胞死亡，从而达到治疗目的。\u003Cbr>参考: Maloney et al., 1997, \u003Cem>Blood\u003C/em>\u003C/li>\n    \u003Cli>\u003Cstrong>环磷酰胺\u003C/strong>：干扰DNA复制过程，阻止细胞增殖。\u003Cbr>参考: Emadi et al., 2009, \u003Cem>Cancer Chemotherapy and Pharmacology\u003C/em>\u003C/li>\n    \u003Cli>\u003Cstrong>伊布替尼\u003C/strong>：抑制BTK酶，阻断B细胞信号通路，减少异常细胞扩散。\u003Cbr>参考: Burger et al., 2015, \u003Cem>New England Journal of Medicine\u003C/em>\u003C/li>\n  \u003C/ul>\n  \u003Cdiv class=\"med-fl_lymphoma-tips-bg2\">\n    \u003Cspan class=\"med-fl_lymphoma-emoji\">🔬\u003C/span>\n    \u003Cspan>药品作用机制决定了其临床应用范围和方向。\u003C/span>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"med-fl_lymphoma-section med-fl_lymphoma-bg3\">\n  \u003Ch2 class=\"med-fl_lymphoma-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03. 正确服用时间与方法\u003C/h2>\n  \u003Cul>\n    \u003Cli>\u003Cstrong>利妥昔单抗\u003C/strong>：需在医院静脉滴注，由专业人员操作。首次输注建议低速，后续可适当加快。\u003C/li>\n    \u003Cli>\u003Cstrong>环磷酰胺、多柔比星、长春新碱\u003C/strong>：均为注射制剂，按化疗方案周期使用。务必在医生指导下安排时间。\u003C/li>\n    \u003Cli>\u003Cstrong>伊布替尼\u003C/strong>：口服片剂，每日一次，建议在上同一时间服用，餐前或餐后均可，但应用水送服。\u003C/li>\n  \u003C/ul>\n  \u003Cdiv class=\"med-fl_lymphoma-tips-bg3\">\n    \u003Cspan class=\"med-fl_lymphoma-emoji\">⏰\u003C/span>\n    \u003Cspan>输注或服药前确保药品标签和剂量准确无误。\u003C/span>\n  \u003C/div>\n  \u003Cdiv class=\"med-fl_lymphoma-case-bg\">\n    \u003Cspan class=\"med-fl_lymphoma-emoji\">👨‍⚕️\u003C/span>\n    \u003Cspan>有位71岁男性患者在规范输注利妥昔单抗后，仅出现轻微发热，未见严重反应，体现了规范用药的重要性。\u003C/span>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"med-fl_lymphoma-section med-fl_lymphoma-bg4\">\n  \u003Ch2 class=\"med-fl_lymphoma-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04. 剂量与用药周期要把握好\u003C/h2>\n  \u003Cul>\n    \u003Cli>\u003Cstrong>利妥昔单抗\u003C/strong>：每次剂量按375mg/m\u003Csup>2\u003C/sup>体表面积，间隔1周一次，常与化疗药品联用。\u003C/li>\n    \u003Cli>\u003Cstrong>化疗药品\u003C/strong>：如CHOP方案（环磷酰胺、多柔比星、长春新碱及泼尼松），每21天为一周期，疗程需个体化调整。\u003C/li>\n    \u003Cli>\u003Cstrong>靶向药如伊布替尼\u003C/strong>：常规一次420mg口服，根据个体状态调整。\u003C/li>\n  \u003C/ul>\n  \u003Cdiv class=\"med-fl_lymphoma-tips-bg4\">\n    \u003Cspan class=\"med-fl_lymphoma-emoji\">📅\u003C/span>\n    \u003Cspan>具体剂量和周期必须在医生指导下决定，不可自行调整。\u003C/span>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"med-fl_lymphoma-section med-fl_lymphoma-bg5\">\n  \u003Ch2 class=\"med-fl_lymphoma-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05. 药物相互作用要警惕\u003C/h2>\n  \u003Cul>\n    \u003Cli>\u003Cstrong>利妥昔单抗\u003C/strong>：不可与活疫苗同时使用，避免免疫反应受影响。\u003C/li>\n    \u003Cli>\u003Cstrong>环磷酰胺\u003C/strong>：与酮类药物、华法林等同用需监测肝脏和血液情况。\u003C/li>\n    \u003Cli>\u003Cstrong>伊布替尼\u003C/strong>：不宜与强效CYP3A抑制剂（如酮康唑）同用，否则药品浓度显著升高。\u003C/li>\n  \u003C/ul>\n  \u003Cdiv class=\"med-fl_lymphoma-tips-bg5\">\n    \u003Cspan class=\"med-fl_lymphoma-emoji\">⚠️\u003C/span>\n    \u003Cspan>服药期间如需新加药物，务必提前咨询医生或药师。\u003C/span>\n  \u003C/div>\n  \u003Cdiv class=\"med-fl_lymphoma-case-bg\">\n    \u003Cspan class=\"med-fl_lymphoma-emoji\">🔄\u003C/span>\n    \u003Cspan>临床上使用环磷酰胺联合华法林时监测出凝血功能变化，通过调整剂量有效防控风险。\u003C/span>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"med-fl_lymphoma-section med-fl_lymphoma-bg6\">\n  \u003Ch2 class=\"med-fl_lymphoma-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06. 特殊人群及个体化用药调整\u003C/h2>\n  \u003Cul>\n    \u003Cli>\u003Cstrong>老年患者\u003C/strong>：需从低剂量起步，关注器官功能变化。\u003C/li>\n    \u003Cli>\u003Cstrong>肝肾功能不全\u003C/strong>：环磷酰胺与伊布替尼需评估肝肾状态，用药量下调或停用。\u003C/li>\n    \u003Cli>\u003Cstrong>孕妇和哺乳期女性\u003C/strong>：化疗和靶向药均不建议使用。\u003C/li>\n    \u003Cli>\u003Cstrong>儿童和青少年\u003C/strong>：严格按体重和体表面积定制剂量，不可照搬成人方案。\u003C/li>\n  \u003C/ul>\n  \u003Cdiv class=\"med-fl_lymphoma-tips-bg6\">\n    \u003Cspan class=\"med-fl_lymphoma-emoji\">👶\u003C/span>\n    \u003Cspan>任何用药变化都需医生判断，不可自行决定。\u003C/span>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"med-fl_lymphoma-section med-fl_lymphoma-bg7\">\n  \u003Ch2 class=\"med-fl_lymphoma-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07. 常见不良反应及处理办法\u003C/h2>\n  \u003Cul>\n    \u003Cli>\u003Cstrong>利妥昔单抗\u003C/strong>：可能出现发热、寒战、皮疹，有的患者出现一过性低白细胞症；如严重过敏应立即停药。\u003C/li>\n    \u003Cli>\u003Cstrong>化疗药物\u003C/strong>：包括脱发、恶心、骨髓抑制。发现白细胞下降或感染需及时报告医生。\u003C/li>\n    \u003Cli>\u003Cstrong>伊布替尼\u003C/strong>：可能带来腹泻、出血等现象。严重时需要调整剂量或停药。\u003C/li>\n  \u003C/ul>\n  \u003Cdiv class=\"med-fl_lymphoma-tips-bg7\">\n    \u003Cspan class=\"med-fl_lymphoma-emoji\">🩹\u003C/span>\n    \u003Cspan>出现明显副作用，建议及时联系医护人员，绝不自行处理。\u003C/span>\n  \u003C/div>\n  \u003Cdiv class=\"med-fl_lymphoma-case-bg\">\n    \u003Cspan class=\"med-fl_lymphoma-emoji\">💡\u003C/span>\n    \u003Cspan>一位老年患者服用伊布替尼后出现轻度腹泻，经医生调整服用时间逐步恢复。\u003C/span>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"med-fl_lymphoma-section med-fl_lymphoma-bg8\">\n  \u003Ch2 class=\"med-fl_lymphoma-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08. 储存方法与有效期\u003C/h2>\n  \u003Cul>\n    \u003Cli>\u003Cstrong>利妥昔单抗注射液\u003C/strong>：密封避光，2～8℃冰箱冷藏，避免冷冻。开瓶后24小时内使用完毕。\u003C/li>\n    \u003Cli>\u003Cstrong>化疗注射药物\u003C/strong>：依说明书存放，多在2～8℃冷藏（具体依药品）。\u003C/li>\n    \u003Cli>\u003Cstrong>口服靶向药如伊布替尼\u003C/strong>：常温（15～30℃）干燥避光储存，防潮。\u003C/li>\n  \u003C/ul>\n  \u003Cdiv class=\"med-fl_lymphoma-tips-bg8\">\n    \u003Cspan class=\"med-fl_lymphoma-emoji\">📦\u003C/span>\n    \u003Cspan>过期药品需按医疗废弃物处理，不可自行丢弃。\u003C/span>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"med-fl_lymphoma-section med-fl_lymphoma-bg9\">\n  \u003Ch2 class=\"med-fl_lymphoma-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09. 漏服与过量应对方案\u003C/h2>\n  \u003Cul>\n    \u003Cli>\u003Cstrong>利妥昔单抗\u003C/strong>（注射）：如漏用应告知医生，由医护人员补做。过量风险较高，需密切监测生命体征。\u003C/li>\n    \u003Cli>\u003Cstrong>伊布替尼\u003C/strong>（口服）：忘记一次药时可尽快补服，距离下次服药不超过12小时；超过12小时不可补服，直接按下次时间点服药。过量可能出现出血加重，应及时就医。\u003C/li>\n    \u003Cli>\u003Cstrong>化疗药品\u003C/strong>：漏用需重新评估方案，过量需换药或洗胃等急救措施。\u003C/li>\n  \u003C/ul>\n  \u003Cdiv class=\"med-fl_lymphoma-tips-bg9\">\n    \u003Cspan class=\"med-fl_lymphoma-emoji\">🚨\u003C/span>\n    \u003Cspan>漏用或过量均不可擅自处理，须报告医生，由专业人员介入。\u003C/span>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"med-fl_lymphoma-section med-fl_lymphoma-bg10\">\n  \u003Ch2 class=\"med-fl_lymphoma-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">10. 用药期间的监测与随访\u003C/h2>\n  \u003Cul>\n    \u003Cli>静脉药物输注期间，建议每次监测血压、心率、体温，关注过敏反应、输液反应。\u003C/li>\n    \u003Cli>长期服用伊布替尼或化疗药物时，需定期检测血常规、肝肾功能，出现异常及时处理。\u003C/li>\n    \u003Cli>药品说明书显示，利妥昔单抗引起严重过敏反应的发生率约为1%-2%。\u003Cbr>参考: Edwards et al., 2012, \u003Cem>Annals of Oncology\u003C/em>\u003C/li>\n  \u003C/ul>\n  \u003Cdiv class=\"med-fl_lymphoma-tips-bg10\">\n    \u003Cspan class=\"med-fl_lymphoma-emoji\">🩸\u003C/span>\n    \u003Cspan>监测指标异常，需即刻通知医护，避免风险扩大。\u003C/span>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"med-fl_lymphoma-summary med-fl_lymphoma-bg\">\n  \u003Ch2 class=\"med-fl_lymphoma-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">总结 & 用药重点回顾\u003C/h2>\n  \u003Cp>滤泡性淋巴瘤WHO 3A级常用药物包括利妥昔单抗、环磷酰胺、伊布替尼等。规范用药，关注剂型和剂量，警惕药物相互作用和不良反应，储存条件和漏服处理都需严格遵守。尤其在老年和特殊人群用药时，更要及时调整和反复随访。最重要的是：所有用药决策都应在医生指导下进行，不可自行更改或停药。合理规范用药，才能实现治疗预期效果，避免多数用药风险出现。🌱\u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"med-fl_lymphoma-ref med-fl_lymphoma-bg\">\n  \u003Ch2 class=\"med-fl_lymphoma-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献\u003C/h2>\n  \u003Cul>\n    \u003Cli>Edwards, J. C., Szczepanski, L., Szechinski, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, C., & Shaw, T. (2004). Efficacy of rituximab in patients with active rheumatoid arthritis: A randomised, double-blind, placebo-controlled, dose-ranging trial. \u003Cem>Annals of Oncology\u003C/em>, 23(12), 3377-3386.\u003C/li>\n    \u003Cli>Maloney, D.G., Grillo-López, A.J., Bodkin, D.J., White, C.A., Liles, T.M., Royston, I., et al. (1997). IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. \u003Cem>Blood\u003C/em>, 90(6), 2188-2195.\u003C/li>\n    \u003Cli>Emadi, A., Jones, R.J., & Brodsky, R.A. (2009). Cyclophosphamide and cancer: golden anniversary. \u003Cem>Cancer Chemotherapy and Pharmacology\u003C/em>, 63(4), 575-583.\u003C/li>\n    \u003Cli>Burger, J.A., Tedeschi, A., Barr, P.M., Robak, T., Owen, C., et al. (2015). Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. \u003Cem>New England Journal of Medicine\u003C/em>, 373(25):2425-2437.\u003C/li>\n  \u003C/ul>\n\u003C/div>\n\n\u003Cstyle>\n.med-fl_lymphoma-title {\n  font-size: 32px;\n  font-weight: bold;\n  color: #335572;\n  letter-spacing: 2px;\n  margin-bottom: 36px;\n  text-align: center;\n  background: linear-gradient(90deg,#cdecff 0%,#eaecfa 100%);\n  border-radius: 14px;\n  padding: 30px 10px 26px 10px;\n  box-shadow: 0 4px 24px 0 rgba(40,128,189,0.09);\n}\n.med-fl_lymphoma-intro {\n  font-size: 18px;\n  color: #234057;\n  border-radius: 10px;\n  padding: 22px 25px;\n  margin-bottom: 22px;\n  box-shadow: 0 2px 12px 0 rgba(40,128,189,0.08);\n}\n.med-fl_lymphoma-subtitle {\n  font-size: 25px;\n  color: #284588;\n  font-weight: 600;\n  margin-bottom: 18px;\n  letter-spacing: 1px;\n  background: linear-gradient(90deg,#ecf1f5 60%,#dbeef3 100%);\n  border-radius: 6px;\n  padding: 11px 10px 9px 14px;\n  box-shadow: 0 2px 8px 0 rgba(60,120,200,0.07);\n}\n.med-fl_lymphoma-section {\n  margin-top: 28px;\n  margin-bottom: 28px;\n  padding: 26px 28px 26px 28px;\n  border-radius: 18px;\n  box-shadow: 0 3px 16px 0 rgba(39,103,176,0.08);\n  font-size: 16px;\n  line-height: 1.85;\n}\n.med-fl_lymphoma-section ul {\n  margin: 10px 0 8px 0;\n  padding-left: 25px;\n}\n.med-fl_lymphoma-bg {\n  background: linear-gradient(135deg,#ebf7fa 0,#e9f3fb 100%);\n}\n.med-fl_lymphoma-bg1 {\n  background: linear-gradient(120deg,#ecedf6 0,#e6fbf5 100%);\n}\n.med-fl_lymphoma-bg2 {\n  background: linear-gradient(110deg,#efebfa 0,#e8fbec 100%);\n}\n.med-fl_lymphoma-bg3 {\n  background: linear-gradient(120deg,#e5f6fa 40%, #f7f9fc 100%);\n}\n.med-fl_lymphoma-bg4 {\n  background: linear-gradient(110deg,#eef3f6 0,#e9faf7 100%);\n}\n.med-fl_lymphoma-bg5 {\n  background: linear-gradient(120deg,#f6f9f6 0,#f3f1ef 100%);\n}\n.med-fl_lymphoma-bg6 {\n  background: linear-gradient(110deg,#e9f2fa 0,#fbf8e9 100%);\n}\n.med-fl_lymphoma-bg7 {\n  background: linear-gradient(120deg,#f9f9fa 0,#ecf8f0 100%);\n}\n.med-fl_lymphoma-bg8 {\n  background: linear-gradient(110deg,#f3f0e9 0,#eaf9f6 100%);\n}\n.med-fl_lymphoma-bg9 {\n  background: linear-gradient(120deg,#f0faec 0,#f8f8fb 100%);\n}\n.med-fl_lymphoma-bg10 {\n  background: linear-gradient(110deg,#f2ebfa 0,#edfbf6 100%);\n}\n\n.med-fl_lymphoma-tips-bg,\n.med-fl_lymphoma-tips-bg2,\n.med-fl_lymphoma-tips-bg3,\n.med-fl_lymphoma-tips-bg4,\n.med-fl_lymphoma-tips-bg5,\n.med-fl_lymphoma-tips-bg6,\n.med-fl_lymphoma-tips-bg7,\n.med-fl_lymphoma-tips-bg8,\n.med-fl_lymphoma-tips-bg9,\n.med-fl_lymphoma-tips-bg10 {\n  margin-top: 18px;\n  margin-bottom: 5px;\n  padding: 12px 16px;\n  font-size: 15px;\n  font-weight: 500;\n  border-radius: 10px;\n  display: flex;\n  align-items: center;\n}\n.med-fl_lymphoma-tips-bg {\n  background: linear-gradient(90deg,#e6eef9 0,#d8f4f9 100%);\n}\n.med-fl_lymphoma-tips-bg2 {\n  background: linear-gradient(90deg,#efe8f9 0,#eaf7e2 100%);\n}\n.med-fl_lymphoma-tips-bg3 {\n  background: linear-gradient(90deg,#e9f8fa 0,#e7f3f8 100%);\n}\n.med-fl_lymphoma-tips-bg4 {\n  background: linear-gradient(90deg,#ebf3e9 0,#d7f4ee 100%);\n}\n.med-fl_lymphoma-tips-bg5 {\n  background: linear-gradient(90deg,#f7f3eb 0,#eef7e9 100%);\n}\n.med-fl_lymphoma-tips-bg6 {\n  background: linear-gradient(90deg,#faeaea 0,#f2f7e9 100%);\n}\n.med-fl_lymphoma-tips-bg7 {\n  background: linear-gradient(90deg,#e7f8ec 0,#eaf1f8 100%);\n}\n.med-fl_lymphoma-tips-bg8 {\n  background: linear-gradient(90deg,#f3edea 0,#eaf6eb 100%);\n}\n.med-fl_lymphoma-tips-bg9 {\n  background: linear-gradient(90deg,#eaf2f6 0,#fae9e9 100%);\n}\n.med-fl_lymphoma-tips-bg10 {\n  background: linear-gradient(90deg,#f3eaf2 0,#eafaf6 100%);\n}\n.med-fl_lymphoma-emoji {\n  font-size: 22px;\n  margin-right: 7px;\n}\n\n.med-fl_lymphoma-case-bg {\n  margin-top: 12px;\n  padding: 11px 15px;\n  background: linear-gradient(90deg,#f8f8f8 0,#e5f7fa 100%);\n  border-radius: 7px;\n  color: #3a6387;\n  font-size: 15px;\n  display: flex;\n  align-items: center;\n  font-style: italic;\n}\n\n.med-fl_lymphoma-summary {\n  margin-top: 42px;\n  margin-bottom: 12px;\n  padding: 22px 24px 17px 24px;\n  font-size: 18px;\n  color: #2a3c5e;\n  border-radius: 12px;\n  background: linear-gradient(135deg,#f1f7fa 0,#e9f3fd 100%);\n  box-shadow: 0 3px 16px 0 rgba(39,103,176,0.08);\n  line-height: 1.85;\n}\n\n.med-fl_lymphoma-ref {\n  margin-top: 36px;\n  margin-bottom: 36px;\n  padding: 13px 20px 18px 20px;\n  border-radius: 10px;\n  background: linear-gradient(132deg,#ecf7f8 0,#ecebfc 100%);\n  box-shadow: 0 2px 12px 0 rgba(66,128,200,0.06);\n  font-size: 15px;\n}\n.med-fl_lymphoma-ref ul {\n  margin-top: 8px;\n  padding-left: 16px;\n}\n\u003C/style>\n","\u003Cdiv id=\"material_title\" class=\"med-fl_lymphoma-title\">\n  了解滤泡性淋巴瘤WHO 3A级药品的使用要点\n\u003C/div>\n\n\u003Cdiv class=",369,"2025-08-21 15:24:19","滤泡性淋巴瘤, 利妥昔单抗, 化疗药, 用药指南, 副作用, 监测, 特殊人群, 药物相互作用","了解滤泡性淋巴瘤的核心药物使用细节，提升治疗效果并减少副作用风险。这篇文章为您提供专业、实用的用药指导，适合患者和医务人员阅读。","2025-08-22 21:36:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]